Related Experiment Video
Updated: Apr 25, 2026
06:15
A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.
Published on: June 14, 2015
8.2K
Tissue-engineered, hydrogel-based endothelial progenitor cell therapy robustly revascularizes ischemic myocardium and
Pavan Atluri1, Jordan S Miller2, Robert J Emery1
1Division of Cardiovascular Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa.
The Journal of Thoracic and Cardiovascular Surgery
|August 18, 2014
Summary
This study introduces a novel hydrogel delivery system for endothelial progenitor cells, significantly improving cell retention and function in heart failure models. The engineered therapy enhances vasculogenesis and preserves heart structure.
Area of Science:
- Regenerative Medicine
- Biomaterials Science
- Cardiovascular Research
Background:
- Cell-based angiogenic therapy for ischemic heart failure faces challenges with low cell retention and dispersion.
- Existing methods result in less than 1% cell retention, limiting clinical impact.
Purpose of the Study:
- To develop a tissue-engineered, hydrogel-based strategy for improved endothelial progenitor cell delivery and retention.
- To overcome limitations of current cell therapies for ischemic heart failure.
Main Methods:
- Endothelial progenitor cells (EPCs) were isolated and encapsulated in fibrin hydrogels.
- EPC-laden hydrogels were implanted onto ischemic rat myocardium following acute myocardial infarction.
- Hemodynamics, vasculogenesis, and ventricular geometry were assessed, with EPC migration tracked using fluorescently labeled cells.
Main Results:
- EPCs maintained high viability (88.7%) in the hydrogel matrix.
- Significant migration of EPCs from the hydrogel to infarcted myocardium was observed compared to direct injection.
- Marked increases in vasculogenesis and significant improvements in ventricular hemodynamics and geometry were noted.
Conclusions:
- A tissue-engineered hydrogel system enhances EPC delivery and retention.
- This therapy promotes vasculogenesis and preserves myocardial structure and function in a heart failure model.
